<code id='B555A64F72'></code><style id='B555A64F72'></style>
    • <acronym id='B555A64F72'></acronym>
      <center id='B555A64F72'><center id='B555A64F72'><tfoot id='B555A64F72'></tfoot></center><abbr id='B555A64F72'><dir id='B555A64F72'><tfoot id='B555A64F72'></tfoot><noframes id='B555A64F72'>

    • <optgroup id='B555A64F72'><strike id='B555A64F72'><sup id='B555A64F72'></sup></strike><code id='B555A64F72'></code></optgroup>
        1. <b id='B555A64F72'><label id='B555A64F72'><select id='B555A64F72'><dt id='B555A64F72'><span id='B555A64F72'></span></dt></select></label></b><u id='B555A64F72'></u>
          <i id='B555A64F72'><strike id='B555A64F72'><tt id='B555A64F72'><pre id='B555A64F72'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:leisure time    Page View:4
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In